Sp1 is a critical regulator of the Wilms' tumor-1 gene
- PMID: 9006935
- DOI: 10.1074/jbc.272.5.2901
Sp1 is a critical regulator of the Wilms' tumor-1 gene
Abstract
We performed deletion analysis of WT1-reporter constructs containing up to 24 kilobases of 5'-flanking and first intron WT1 sequence in stably transfected cultured cells as an unbiased approach to identify cis elements critical for WT1 transcription. Although not a tissue-specific element, a proximate 9-base pair CTC repeat accounted for approximately 80% of WT1 transcription in this assay. Enhancer activity of the element and mutated versions correlated completely with their ability to form a DNA-protein complex in gel shifts. Antibody supershift, oligonucleotide competition, and Southwestern studies indicated that the CTC-binding factor is the transcriptional activator Sp1. Sp1 binds the CTC repeat with an affinity, KD = 0.37 nM, at least as high as the consensus GC box. Similar CTC repeats are found in promoters of other growth-related genes. Because Sp1 is important for WT1 expression, we examined Sp1 immunohistochemistry in fetal and adult kidney. In a pattern that precedes that of WT1 message, Sp1 immunostaining was highest in uninduced mesenchyme, early tubules, developing podocytes, and mature glomeruli, but was minimal in mature proximal tubules. This work suggests abundant Sp1 may be a prerequisite for WT1 expression, and that Sp1 may have a wider role in nephrogenesis.
Similar articles
-
A far upstream cis-element is required for Wilms' tumor-1 (WT1) gene expression in renal cell culture.J Biol Chem. 1997 Dec 26;272(52):32836-46. doi: 10.1074/jbc.272.52.32836. J Biol Chem. 1997. PMID: 9407061
-
Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus.J Biol Chem. 1993 Oct 5;268(28):21271-5. J Biol Chem. 1993. PMID: 8407965
-
The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1).Oncogene. 1996 Aug 1;13(3):447-53. Oncogene. 1996. PMID: 8760285
-
Regulation of nov by WT1: a potential role for nov in nephrogenesis.Oncogene. 1996 Apr 4;12(7):1479-92. Oncogene. 1996. PMID: 8622864
-
Does the Wilms' tumour suppressor gene, WT1, play roles in both splicing and transcription?J Cell Sci Suppl. 1995;19:95-9. doi: 10.1242/jcs.1995.supplement_19.14. J Cell Sci Suppl. 1995. PMID: 8655654 Review.
Cited by
-
Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.Oncogene. 2016 Feb 25;35(8):1003-14. doi: 10.1038/onc.2015.154. Epub 2015 May 11. Oncogene. 2016. PMID: 25961914
-
Candidate genes and potential targets for therapeutics in Wilms' tumour.Clin Transl Oncol. 2010 Sep;12(9):597-605. doi: 10.1007/s12094-010-0564-y. Clin Transl Oncol. 2010. PMID: 20851800 Review.
-
miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level.J Exp Clin Cancer Res. 2011 Dec 1;30(1):110. doi: 10.1186/1756-9966-30-110. J Exp Clin Cancer Res. 2011. PMID: 22133358 Free PMC article.
-
The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.Breast Cancer Res. 2007;9(4):R43. doi: 10.1186/bcr1743. Breast Cancer Res. 2007. PMID: 17634147 Free PMC article.
-
Despite WT1 binding sites in the promoter region of human and mouse nucleoporin glycoprotein 210, WT1 does not influence expression of GP210.J Negat Results Biomed. 2004 Dec 21;3:7. doi: 10.1186/1477-5751-3-7. J Negat Results Biomed. 2004. PMID: 15613247 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous